Corrigendum

Immune cell–derived opioids protect against neuropathic pain in mice

Dominika Labuz, Yvonne Schmidt, Anja Schreiter, Heike L. Rittner, Shaaban A. Mousa and Halina Machelska

Published April 1, 2009

Original citation: J. Clin. Invest. 119:278–286 (2009). doi:10.1172/JCI36246.

Citation for this corrigendum: J. Clin. Invest. 119:1051 (2009). doi:10.1172/JCI36246C1.

During the preparation of the manuscript, the END and ENK images on the left side of Figure 1C were inadvertently transposed. The correct Figure 1C appears below.

In the Discussion, the final sentence of the first paragraph should read:

Our current study offers a possible advancement in neuropathic pain therapy based on the utilization of the physiological functions of leukocyte-derived opioids that represents control of painful neuropathies without CNS side effects.

In the legend to Figure 5, the penultimate sentence should read:

Right panels at 2 days and 14 days following CCI: Injection (s.c.) at the neck of the most effective near-nerve doses of CTOP (0.25 µg), ICI 174,864 (2 µg), norBNI (10 µg), and NLXM (5 µg) did not reverse near-nerve CRF-induced (20 ng at 2 days or 100 ng at 14 days) analgesia (P > 0.05; ANOVA).

The authors regret the errors.